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University of California
he US National Institute of Mental Health
(NIMH) developed the Measurement and Treatment
Research to Improve Cognition in Schizophrenia
(MATRICS) initiative for a number of reasons: (i) there
is a widespread belief that too few innovative new drugs
are being developed for illnesses that affect the central
nervous system (CNS) in comparison to other areas of
medicine1; (ii) drugs for CNS disorders have often been
accidental discoveries rather than the products of well-
developed scientific strategies2; and (iii) there is dissatis-
faction with the effectiveness of drugs for schizophrenia.
Evidence for this comes from the recent publication of a
large trial comparing the effectiveness and side effects of
several second-generation antipsychotics known as the
Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) trial.3 In this study, 74% of patients were dis-
continued from their antipsychotic treatment due to lack
of efficacy or side effects.
The results of the CATIE trial emphasize that there are
important limitations in what antipsychotics can do for
patients. Patients and clinicians tend to be dissatisfied
with the clinical response or the tolerability of available
agents. In addition, the widespread availability of these
drugs has not resulted in long-term improvements in the
outcome of schizophrenia.4 These observations, along
with the recent interest in recovery and improving func-
tional outcomes, suggest that drug development for schiz-
ophrenia should focus on targets other than dopamine
D2 receptors.
Impaired neurocognition in schizophrenia
The focus on neurocognition is based on a number of
factors. First, impairments in neurocognition are core
features of schizophrenia. These impairments are pre-
sent during acute exacerbations of the illnesses and dur-
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The US National Institute of Mental Health supported an
initiative to facilitate the development of pharmacologi-
cal agents for enhancing neurocognition in patients with
schizophrenia. This has been accomplished through a con-
sensus-building process that has included representatives
from academia, the pharmaceutical industry, and gov-
ernment. The group has addressed obstacles to drug
development that include (i) the lack of a well-accepted
instrument for measuring neurocognition in clinical trials;
(ii) the lack of a consensus on the best molecular target or
targets for drug development; (iii) the lack of a consensus
regarding the optimal trial design for either comedication
that improves cognition when added to an antipsychotic
or a broad spectrum agent that improves cognition and
treats psychosis; and (iv) the approaches of regulatory
agencies such as the US Food and Drug Administration to
approving and labeling a new agent.     
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ing periods of remission. In addition, first- and second-
generation antipsychotics are relatively ineffective at
treating these symptoms. Patients treated with these
agents tend to have continuing deficits even when ade-
quately treated with antipsychotics.5 Further, the neu-
rocognitive deficits tend to be relatively severe.A meta-
analysis by Heinrichs and Zakzanis6 demonstrates that
the impairments in schizophrenia are particularly severe
for memory, attention, and executive function. In these
areas, individuals with schizophrenia—on average—per-
formed 1.5 standard deviations below community
norms.
The most important reason for the focus on neurocogni-
tion may be that these impairments appear to be related
to the functional outcomes of patients. A review by
Green7 found that the impairments in social and voca-
tional functioning in schizophrenia were strongly related
to the impairments in neurocognition. The magnitudes
for the relationships between cognitive deficits and func-
tional outcome are medium for individual cognitive con-
structs such as attention or working memory, but the rela-
tionships can be strong when summary scores (eg,
composites of several cognitive functions) are used.8-10
This literature on cognitive linkages to functional out-
come provides a compelling rationale for intervention
development at the level of cognition.
In contrast to cognitive deficits, clinical symptoms are
only weakly related to functional outcome in schizo-
phrenia.
Facilitating drug development
Hyman and Fenton2 have suggested a strategy for drug
development that focuses on dissecting psychiatric dis-
orders into component dimensions of psychopathology
that may be more closely related to pathophysiological
processes. These components rather than the illnesses
themselves may be more amenable to novel pharmaco-
logical approaches to therapeutics.This strategy encour-
ages the development of new therapeutics for schizo-
phrenia that move beyond positive symptoms as clinical
targets to focus on dimensions of the illness most associ-
ated with functional disability.
The goal of the MATRICS initiative is to address impor-
tant obstacles that are likely to interfere with the devel-
opment of new pharmacological approaches to improv-
ing neurocognition in schizophrenia. These obstacles
include (i) the lack of a well-accepted instrument for
measuring neurocognition in clinical trials; (ii) the lack
of a consensus on the best molecular target or targets for
drug development; (iii) the lack of a consensus regarding
the optimal trial design for either comedication that
improves cognition when added to an antipsychotic or
a broad-spectrum agent that improves cognition and
treats psychosis; and (iv) the approaches of regulatory
agencies such as the US Food and Drug Administration
(FDA) to approving and labeling a new agent. The
MATRICS group has attempted to address each of these
obstacles.
Development of the MATRICS battery
The selection of the MATRICS battery emerged from a
2-year process that involved a broad range of individuals
from academia, industry, and government. The process
began with a process for determining the domains of
neurocognition that would be evaluated as well as the cri-
teria for selecting tests for each domain. The domains
emerged from both factor analysis of existing databases
and expert opinion.11 Expert opinion was used to priori-
tize the criteria for test selection. Table I lists the criteria
for test selection.
Approximately 90 tests were proposed for measuring
performance in the eight domains.The characteristics of
each test were evaluated and candidates were narrowed
to 36. These tests were graded according to the criteria
in Table I and further narrowed to one or two tests in
each domain. These tests were then evaluated in a five-
site MATRICS Psychometrics and Standardization
Study. The tests were compared with one another in a
diverse group of patients with schizophrenia.The results
led to the final selection of the battery, which is listed in
Table II.
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Table I. Essential criteria for a consensus cognitive battery for clinical trials in
schizophrenia.
• Valid assessment of cognition at the level of all individual
major cognitive domains
• Inclusion of the following cognitive domains: speed of
processing, attention/vigilance, working memory, verbal
learning and memory, visual learning and memory, reason-
ing and problem solving, and social cognition
• High test-retest reliability
• High utility as a repeated measure
• Demonstrated relationship to functional outcome
• Demonstrated tolerability and practicality
Co-primary measures
At one of the MATRICS meetings, Thomas Laughren
from the FDA confirmed that cognition in schizophrenia
was a reasonable clinical target, but that his agency was
unlikely to approve a drug based only on improvement
on a neuropsychological test.Approval would require an
outcome with greater face validity, though it would not
be necessary to demonstrate that a drug actually
improved patient functioning. He did agree that reason-
able coprimary measures would be functional capacity
measures or proxy measures that demonstrate an indi-
vidual’s ability to perform a task, and not whether they
actually do it or a patient or caregiver’s interview-based
assessment of cognition.
With this in mind, we evaluated a number of potential
measures of functional capacity and interview-based mea-
sures of cognition in the psychometric study. One instru-
ment was selected to represent each domain: the Social
Functioning Scale (SFS),12 the SCORS (R. Keefe, personal
communication), the Maryland Assessment of Social
Competence (MASC),13 and the UCSD Performance-
Based Skills Assessment (UPSA).14 The Clinical Global
Impression (CGI)–Cogs (Bilder et al, personal communi-
cation) was added at a later time as an alternative inter-
view-based measure.These measures were administered
along with the MATRICS battery in the psychometric
study and evaluated using similar criteria for the selection
neuropsychological tests.The results indicated that all of
the measures had reasonable psychometric properties. In
addition, the measures had modest relationships with func-
tioning and strong relationships with cognition.
Trial design
An FDA-MATRICS consensus meeting on trial design
brought together a group of neuropsychologists, clinical
trialists, industry representatives, and representatives
from the NIMH and the FDA. The meeting included a
wide-ranging discussion of issues including subject selec-
tion, statistical issues, and design issues. The meeting
focused on issues that should be addressed for either a
comedication that would be added to an antipsychotic or
a broad-spectrum antipsychotic that would be effective
for psychotic symptoms and at enhancing cognition.The
consensus recommendations are published in a special
article by Robert Buchanan in Schizophrenia Bulletin.15
Here are some of the recommendations:
• Include subjects who are clinically stable.
• Exclude subjects only if impairment compromises test
validity or if they perform at ceiling.
• For comedication, compare addition of drug or placebo
to current antipsychotic.
• For a broad-spectrum antipsychotic, compare experi-
mental drug to an antipsychotic that does not impair
cognition.
• Monitor outcome with MATRICS battery and a copri-
mary measure of functional capacity or interview-based
cognitive assessment.
Molecular targets
We also developed a process to develop a consensus
regarding the molecular targets that should be a focus of
drug development. This was carried out under the lead-
The NIMH-MATRICS project - Marder Dialogues in Clinical Neuroscience - Vol 8 . No. 1 . 2006
111
Table II. The Provisional Cognitive Consensus Battery. The final composition
of the battery will depend on reaching appropriate agreements for
licensing and distribution of tests with the respective test develop-
ers and publishers. Once these agreements have been reached, the
final consensus battery will be posted on the MATRICS Web site.
Speed of processing Administration
time (min)
Category Fluency 2.0
Brief Assessment of Cognition in 
Schizophrenia (BACS) – Symbol-Coding 3.0
Trail Making A 2.1
Attention/vigilance
Continuous Performance Test – 
Identical Pairs (CPT-IP) 13.4
Working memory
Verbal: University of Maryland – 
Letter-Number Span 5.9
Nonverbal: Wechsler Memory Scale (WMS) – 
III Spatial Span 5.1
Verbal learning
Hopkins Verbal Learning Test (HVLT) – Revised 4.1
Visual learning
Brief Visuospatial Memory Test (BVMT) – Revised 4.7
Reasoning and problem solving
Neuropsychological Assessment Battery (NAB) – 
Mazes 11.2
Social cognition
Mayer-Salovey-Caruso Emotional Intelligence 
Test (MSCEIT) – Managing Emotions 12.0
Total estimated administration time of 
Provisional Cognitive Consensus Battery 63.5
ership of Carol Tamminga and Mark Geyer. We first
interviewed a large group of neuroscientists and asked
them to rank the targets. We then assembled a group of
experts at an open meeting at the National Institutes of
Health in Bethesda, Maryland. Proponents of each tar-
get presented the evidence for each target and there was
a broad open discussion of each. After the meeting the
group was surveyed leading to this list of targets. Table
III provides the ranking of the first 9 targets. α7-Nicotinic
agonists and dopamine D1 agonists were viewed as par-
ticularly promising.There was also considerable interest
in subtypes of glutamate receptors.
Other activities in this area are currently taking place as
MATRICS activities are completed. First, the MATRICS
battery is being assembled so that it can be purchased as
a single package. Second, NIMH has funded a trials net-
work that is initiating studies of promising drugs. ❏
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Table III. Measurement and Treatment Research to Improve Cognition in
Schizophrenia (MATRICS) ranking of targets. AMPA, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionate; GABA, γ-aminobutyric
acid; NMDA, N-methyl-D-aspartate.
Target Ranking
α7-Nicotinic receptor agonists 1
Dopamine D1 receptor agonists 2
AMPA glutamatergic receptor agonists 3
α2-adrenergic receptor agonists 4
NMDA glutamatergic receptor agonists 5
Metabotropic glutamate receptor agonists 6
Glycine reuptake inhibitors 7
M1 muscarinic receptor agonists 8
GABAA R subtype selective agonists 9
El proyecto MATRICS del NIMH para 
desarrollar agentes que mejoren la 
cognición en la esquizofrenia
El Instituto Nacional de Salud Mental de los Estados
Unidos ha financiado una iniciativa para facilitar el
desarrollo de psicofármacos para mejorar la neuro-
cognición en pacientes con esquizofrenia. Esto se
ha llevado a cabo  mediante un proceso consen-
suado en que se han incluido representantes del
mundo académico, de la industria farmacéutica y
del gobierno. El grupo ha señalado los obstáculos
para el desarrollo de fármacos, los que incluyen: (i)
la falta de un instrumento bien aceptado para
medir la neurocognición en los ensayos clínicos, (ii)
la falta de consenso respecto al mejor o los mejores
objetivos moleculares para el desarrollo de fárma-
cos, (iii) la falta de consenso respecto al diseño de
ensayos óptimos tanto para la comedicación que
mejore la cognición cuando se asocia a un antipsi-
cótico como para un fármaco de amplio espectro
que mejore la cognición y trate la psicosis y (iv) los
procedimientos de las agencias reguladoras, como
la FDA de los Estados Unidos, para aprobar y clasi-
ficar un nuevo fármaco.    
Le projet NIMH-MATRICS pour développer
des agents stimulant la cognition dans la
schizophrénie
L’institut national américain de santé mentale a
soutenu une initiative pour permettre le dévelop-
pement de médicaments stimulant la neurocogni-
tion des patients atteints de schizophrénie. Un
regroupement consensuel comprenant des repré-
sentants de l’académie, de l’industrie pharmaceuti-
que et du gouvernement a permis d’y arriver. Le
groupe a présenté les obstacles au développement
des médicaments : 1°: le manque d’instruments fai-
sant l’unanimité pour mesurer la neurocognition
dans les études cliniques ; 2°: le manque de con-
sensus sur la meilleure cible moléculaire ou sur les
cibles pour développer les médicaments ; 3°: le
manque de consensus vis-à-vis du schéma optimal
à adopter pour l’étude soit d’une comédication
améliorant la cognition lorsqu’elle est ajoutée à un
antipsychotique soit d’une molécule à large spectre
améliorant la cognition et traitant la psychose ; et
4°: l’approche des administrations telles que la FDA
(Food and Drug Administration) pour homologuer
et cataloguer un nouveau médicament.
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